Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00430677 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 423
- Enrollment target
NCT00430677 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 423 participants.
The verdict
NCT00430677, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 423 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn if addition of abatacept is safe and improves the effectiveness of treatment of patients with active lupus nephritis who are also taking mycophenolate mofetil (MMF) and corticosteroids.
Interventions
- DRUG Abatacept
- DRUG Mycophenolate mofetil (MMF)
- DRUG Corticosteroids (prednisone or prednisolone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 423 participants |
| Start Date | 2007-06 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00430677
The ClinicalTrials.gov registry entry for NCT00430677 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 423 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Abatacept is the first listed.
NCT00430677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00430677 about?
NCT00430677 is a clinical study titled "Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis". The purpose of this clinical research study is to learn if addition of abatacept is safe and improves the effectiveness of treatment of patients with active lupus nephritis who are also taking mycophenolate mofetil (MMF) and corticosteroids.
What is the current status of trial NCT00430677?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 423 participants. The study started on 2007-06. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00430677?
The interventions under investigation include: Abatacept (DRUG), Mycophenolate mofetil (MMF) (DRUG), Corticosteroids (prednisone or prednisolone) (DRUG).
Who is sponsoring clinical trial NCT00430677?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.